Literature DB >> 10579482

Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.

D S Streetman1, R E Ellis, A N Nafziger, J S Leeder, A Gaedigk, R Gotschall, G L Kearns, J S Bertino.   

Abstract

Most dextromethorphan CYP2D6 phenotyping studies use a 30-mg dose, but data that show superiority of any particular dose are lacking. We compared metabolic ratios from six different dextromethorphan phenotyping doses to ascertain whether linearity existed over a dosage range. Forty subjects were enrolled in the study. Each subject received 0.05 mg/kg, 0.15 mg/kg, 0.3 mg/kg, 30 mg, 0.8 mg/kg, and 1.2 mg/kg dextromethorphan in a randomized crossover fashion. Urinary dextromethorphan to dextrorphan molar ratios were used to measure CYP2D6 activity. Single blood samples were obtained for CYP2D6 genotyping, which revealed one poor metabolizer and 39 extensive metabolizers. A statistical difference was found for the molar ratio between the 0.8 mg/kg and the 1.2 mg/kg dose compared with the other four doses. None of the 39 genotypic extensive metabolizers were incorrectly phenotyped with any of these doses. These data support the use of moderate doses of dextromethorphan for phenotyping to avoid dose dependency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579482     DOI: 10.1016/S0009-9236(99)70018-4

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

Review 2.  Addressing phenoconversion: the Achilles' heel of personalized medicine.

Authors:  Rashmi R Shah; Robert L Smith
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

3.  Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.

Authors:  Christian Funck-Brentano; Pierre-Yves Boëlle; Céline Verstuyft; Célia Bornert; Laurent Becquemont; Jean-Marie Poirier
Journal:  Eur J Clin Pharmacol       Date:  2005-11-17       Impact factor: 2.953

4.  A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence.

Authors:  J Steven Leeder; Andrea Gaedigk; Krista J Wright; Vincent S Staggs; Sarah E Soden; Yvonne S Lin; Robin E Pearce
Journal:  Clin Transl Sci       Date:  2022-08-23       Impact factor: 4.438

Review 5.  Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics.

Authors:  Andrea Gaedigk; Jean C Dinh; Hyunyoung Jeong; Bhagwat Prasad; J Steven Leeder
Journal:  J Pers Med       Date:  2018-04-17

6.  Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial.

Authors:  Manuela Vay; Marleen Julia Meyer; Antje Blank; Gisela Skopp; Peter Rose; Mladen Vassilev Tzvetkov; Gerd Mikus
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

7.  Prediction and visualization of CYP2D6 genotype-based phenotype using clustering algorithms.

Authors:  Eun-Young Kim; Sang-Goo Shin; Jae-Gook Shin
Journal:  Transl Clin Pharmacol       Date:  2017-09-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.